Singapore markets close in 3 hours 57 minutes
Straits Times Index
3,239.69 +3.61 (+0.11%) Nikkei
27,910.86 +336.43 (+1.22%) Hang Seng
19,769.42 +319.19 (+1.64%) FTSE 100
7,472.17 -17.02 (-0.23%) BTC-USD
17,211.60 +385.25 (+2.29%) CMC Crypto 200
406.00 +11.32 (+2.87%)
Novartis AG (NVSEF)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
At close: 01:00PM EST
| Previous close | 91.00 |
| Open | 91.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 91.00 - 91.00 |
| 52-week range | 72.98 - 93.58 |
| Volume | |
| Avg. volume | 38,976 |
| Market cap | 200.172B |
| Beta (5Y monthly) | 0.49 |
| PE ratio (TTM) | 9.38 |
| EPS (TTM) | 9.70 |
| Earnings date | N/A |
| Forward dividend & yield | 3.35 (3.71%) |
| Ex-dividend date | 08 Mar 2022 |
| 1y target est | N/A |
- Zacks
Novartis' (NVS) PNH Candidate Achieves Study Objectives
Novartis' (NVS) phase III study APPOINT-PNH evaluating investigational oral monotherapy iptacopan in complement-inhibitor-naive (including anti-C5 therapies) adults with PNH meets its primary endpoint.
- Zacks
Emergent (EBS) OTC Narcan Filing Gets FDA Priority Review Tag
The FDA grants priority review to Emergent's regulatory filing seeking approval for an OTC version of its Narcan nasal spray. A final decision is expected by March 2023-end.
- Zacks
Novartis' (NVS) Pluvicto Meets Goal in 2nd Prostate Cancer Study
Novartis' (NVS) phase III PSMAfore study evaluating Pluvicto for treating patients with PSMA-positive metastatic castration-resistant prostate cancer meets primary endpoint.
© 2022 Yahoo. All rights reserved.
